JPH0229670B2 - - Google Patents
Info
- Publication number
- JPH0229670B2 JPH0229670B2 JP57031818A JP3181882A JPH0229670B2 JP H0229670 B2 JPH0229670 B2 JP H0229670B2 JP 57031818 A JP57031818 A JP 57031818A JP 3181882 A JP3181882 A JP 3181882A JP H0229670 B2 JPH0229670 B2 JP H0229670B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- boc
- residue
- group
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000000524 functional group Chemical group 0.000 claims description 2
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 claims 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- -1 amino acid chlorides Chemical class 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000008206 alpha-amino acids Nutrition 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 150000001414 amino alcohols Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- MLAPMZGXJGUYNO-INIZCTEOSA-N benzyl n-[(5s)-6-hydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]hexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO)CCCCNC(=O)OCC1=CC=CC=C1 MLAPMZGXJGUYNO-INIZCTEOSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- ZAVSPTOJKOFMTA-SFHVURJKSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoic acid Chemical compound C1=CC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C1OCC1=CC=CC=C1 ZAVSPTOJKOFMTA-SFHVURJKSA-N 0.000 description 1
- BDHUTRNYBGWPBL-HNNXBMFYSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 BDHUTRNYBGWPBL-HNNXBMFYSA-N 0.000 description 1
- AQTUACKQXJNHFQ-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-LURJTMIESA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 description 1
- CQIUZHAQYHXKRY-VIFPVBQESA-N (2s)-2-amino-3-phenylpropanal Chemical compound O=C[C@@H](N)CC1=CC=CC=C1 CQIUZHAQYHXKRY-VIFPVBQESA-N 0.000 description 1
- RRONHWAVOYADJL-HNNXBMFYSA-N (2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-HNNXBMFYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FCAJYRVEBULFKS-UHFFFAOYSA-N 2-(oxolan-2-yl)ethanol Chemical compound OCCC1CCCO1 FCAJYRVEBULFKS-UHFFFAOYSA-N 0.000 description 1
- QJYRUYURLPTHLR-YFKPBYRVSA-N 2-[(4s)-4-amino-5-oxopentyl]guanidine Chemical compound O=C[C@@H](N)CCCNC(N)=N QJYRUYURLPTHLR-YFKPBYRVSA-N 0.000 description 1
- QPMCUNAXNMSGTK-UHFFFAOYSA-N 2-aminopropanal Chemical compound CC(N)C=O QPMCUNAXNMSGTK-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 238000006828 Rosenmund reduction reaction Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
- 108010052590 amastatin Proteins 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108010039262 elastatinal Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- FOMAWYQEBPYJJU-SFHVURJKSA-N tert-butyl n-[(2s)-1-hydroxy-3-(4-phenylmethoxyphenyl)propan-2-yl]carbamate Chemical compound C1=CC(C[C@@H](CO)NC(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 FOMAWYQEBPYJJU-SFHVURJKSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Description
本発明は光学活性β―アミノアルコール類を原
料として、このものを酸化することにより光学活
性α―アミノアルデヒド類及びペプチドアルデヒ
ド類の親規製造法に関する。光学活性α―アミノ
アルデヒド類はベスタチン、ペプスタチン、アマ
スタチン等の合成中間体として有用な化合物であ
る。一方光学活性ペプチドアルデヒド類は微生物
が産生する酵素阻害剤としてこれまでにロイペプ
チン、アンチパイン、キモスタチン、エラスタチ
ナールが見出されているが、これらはC末端残基
としてそれぞれアルギニナール、フエニルアラニ
ナール、アラニナールを含んでいる。これらの光
学活性ペプチドアルデヒド類は各種プロテアー
ゼ、例えばプラスミン、トリプシン、パパイン、
キモトリプシン、エステラーゼ等を強く阻害す
る。このほかにこれら酵素阻害剤は消炎作用、抗
潰瘍作用、変異誘発阻止、腹水貯留阻止、発癌な
らびに癌転移阻止などをはじめとし、多くの疾病
に対する効果が報告され、近年脚光をあびてい
る。
α―アミノアルデヒド類合成の従来方法はα―
アミノ酸誘導体の還元法とα―アミノ酸由来のβ
―アミノアルコール類の酸化法によるものに大別
できる。還元法としてはN―保護基α―アミノ酸
エステルのナトリウムアマルガム還元(J.Biol.
Chem.,217巻、317頁、1955年)、水素化ジイソ
ブチルアルミニウム還元(Chem.Pharm.Bull.,
23巻、3081頁、1975年)、N―フタロイル―α―
アミノ酸塩化物のローゼンムント還元(J.Org.
Chem.,18巻、297頁、1953年)、N―保護α―ア
ミノ酸ピラゾリドあるいは3,5―ジメチルピラ
ゾリドの水素化リチウムアルミニウム還元
(Ann.,640巻、11頁、1961年、J.Antibiotics,
29巻、600頁、1976年、J.Med.Chem.,20巻、510
頁、1977年)、N―保護α―アミノ酸イミダゾリ
ドの水素化ジイソブチルアルミニウム還元(J.C.
S.Chem.Comm.,79頁、1979年)及びN―保護
α―アミノ酸混合酸無水物の接触還元(Chem.
Pharm.Bull.,30巻、361頁、1972年)等が知ら
れているが、これらはいずれも原料及び副生物の
混合物として得られ、α―アミノアルデヒド類が
シリカゲル等の精製手段に不安定でラセミ化する
ことから単一の光学的純品としてα―アミノアル
デヒド類を得るに至つていない。このため公知の
還元法はα―アミノアルデヒドのアルデヒド部を
保護して精製し、脱保護するという二工程の操作
を必要とし、また収率も低いという欠点を有す
る。また酸化法としてはβ―アミノアルコール類
のフイツナー・モフアツト酸化(Chem.Pharm.
Bull.,20巻、361頁、1972年)、クロム酸―ピリ
ジン酸化(J.Org.Chem.,46巻、4797頁、1981
年)が知られているが、これらはいずれも大部分
ラセミ化したα―アミノアルデヒド類を得ている
のみである。またα―アミノ酸より誘導した3―
アミノ―1,2―ジオール類の過ヨウ素酸を用い
るグリコール酸化開裂により光学活性体を得てい
る例もあるがα―アミノ酸からの工程数が長く実
用性に乏しく、また一般性も確かめられていない
(J.C.S.Chem.Comm.,875頁、1979年)。
以上の如く公知方法は収率が低い、あるいは精
製のためアルデヒド基を保護しなければならなか
つたり、あるいは工程数が長いなどの欠点を有し
満足し難い方法である。このためα―アミノアル
デヒド類の光学的純品の物性値等は現在までほと
んど知られていない。そこで本発明者等は種々研
究を行なつた結果、三酸化イオウ錯体とジメチル
スルホキシドをトリエチルアミン存在下で光学活
性β―アミノアルコール類あるいはペプチドアル
コール類に作用させ短時間酸化することにより収
率良く光学活性α―アミノアルデヒド類あるいは
ペプチドアルデヒド類を光学的純品として得る新
規な製造法を発見し本発明を完成した。なお、J.
A.C.S.,86巻、5505頁、1967年に記載の如くアル
コール類を酸化してアルデヒド類にする報告は知
られているが、本発明のように光学活性β―アミ
ノアルコール類から光学活性α―アミノアルデヒ
ド類を製造した報告は未だ見当らず、しかも本発
明方法を行なうことにより後記記載の様な優れた
光学活性α―アミノアルデヒド類又はペプチドア
ルデヒド類の製造が可能となつたものである。
本発明方法を化学式で表わすと下式の通りであ
る。
(式中R1はアミノ保護基、アミノ酸残基、ペ
プチド残基、官能基の全部又は一部を保護したア
ミノ酸残基またはペプチド残基、R2及びR4は水
素原子又はアルキル基、R3は水素原子、アルキ
ル基もしくはアリール基であり、アルキル基及び
アリール基は無置換であつてもよく置換されてい
てもよい。)
なお、R1に係るアミノ保護基としてはペプチ
ド合成等に通常使用される第三ブトキシカルボニ
ル基、カルボベンゾキシ基、ベンジル基、トシル
基等が使用可能である。また、R3に関しては具
体的にメチル、エチル、プロピル、イソプロピ
ル、ブチル、イソブチル、1―メチルプロピル、
カルボキシメチル、0―ベンジルオキシメチル、
β―カルボキシエチル、β―メチルチオエチル、
ベンジル、S―ベンジルチオメチル、4―ベンジ
ルオキシベンジル、3,4―ジメトキシベンジ
ル、イミダゾリルメチル、3,4―メチレンジオ
キシベンジル、フエニル、4―ベンジルオキシフ
エニル、N〓―ニトログアニジノプロピル、N〓―
Boc―アミノブチル、N〓―Boc―アミノプロピ
ル、インドリルメチル基等である。
次に本発明方法について説明する。
前記記載の(1)式で示したβ―アミノアルコール
あるいはペプチドアルコールの合成法としては、
種々の合成法を応用することができるが、1例と
して示せば次の通りである。
先ず、N―保護アミノ酸をメタノール―ベンゼ
ン混合溶媒に溶解し、トリメチルシリルジアゾメ
タンを室温で反応させた後、反応溶媒を減圧下に
留去し、反応容器をアルゴンガス等で置換した後
テトラヒドロフラン・エタノール溶媒に溶解し、
塩化リチウム及び水素化ホウ素ナトリウムを加え
室温下に反応させることによつて容易にβ―アミ
ノアルコールとすることができる。生成物の単離
方法としては反応液より溶媒を留去した後、常法
に従い塩化メチレン等の溶媒で抽出、洗浄、乾燥
した後溶媒を留去することによつて容易に結晶又
は油状物として得ることができる。一方、ペプチ
ドアルコールは常法の手段でペプチドのメチルエ
ステルを得、このものにテトラハイドロフラン、
塩化リチウム、水素化ホウ素ナトリウムとエタノ
ールを加え、アルゴンガス下で反応させて得るこ
とができる。得られた生成物はそのまま次の反応
に使用することもできるが、適当な溶媒、例えば
n―ヘキサン、酢酸エチル、塩化メチレン、エー
テル・n―ヘキサン、酢酸エチル・n―ヘキサン
等で再結晶精製又は減圧蒸留もしくはカラムクロ
マトグラフイーで精製を行ない次の反応に使用す
る方が好ましい。次に、このβ―アミノアルコー
ルあるいはペプチドアルコールとトリエチルアミ
ンを無水ジメチルスルホキシド中で混合し三酸化
イオウ錯体の無水ジメチルスルホキシド溶液を添
加して酸化すれば光学活性α―アミノアルデヒド
あるいはペプチドアルデヒドが生成する。使用す
るトリエチルアミンと三酸化イオウ錯体の量は
各々2.5当量あれば充分であるが、約3当量使用
する条件が適当である。三酸化イオウ錯体として
は三酸化イオウとピリジン、ジオキサン、トリメ
チルアミン又はDMF等との錯体が使用できる。
反応時間は数分〜十数分で充分であり、また反応
温度は室温で行なうことができる。溶媒としては
無水ジメチルスルホキシドがその働きをするが、
必要によりベンゼン、塩化メチレン等も使用可能
である。反応終了後反応混合物を氷水中にあけ生
成物を適宜の溶媒、例えばエーテルあるいは酢酸
エチル―ベンゼン(4:1)等に溶解し、クエン
酸水溶液、水、飽和重曹水等で洗浄したのち乾燥
し溶媒を留去すると生成物として光学活性α―ア
ミノアルデヒド類及びペプチドアルデヒド類を得
る。得られた光学活性α―アミノアルデヒド類及
びペプチドアルデヒド類は何ら精製することなく
酵素阻害剤等に使用できるが結晶性のものは適当
な溶媒より再結晶できる。
以上の如く本発明方法はα―アミノ酸より容易
に得られるβ―アミノアルコールから簡単な操作
で高収率、高光学純度でα―アミノアルデヒドを
製造する新規な方法を提供するもので、以下参考
例、実施例を以て本発明を説明するが、本発明の
範囲がこれにより限定されるものではない。なお
文中の略号は各々次の意味を表わすものとする。
Ala:アラニン残基
Val:バリン残基
Leu:ロイシン残基
Pro:プロリン残基
Met:メチオニン残基
Trp:トリプトフアン残基
Tyr:チロシン残基
Lys:リジン残基
Glu:グルタミン酸残基
Cys:システイン残基
Arg:アルギニン残基
Phe:フエニルアラニン残基
Gly:グリシン残基
Boc:第三ブトキシカルボニル基
Z:カルボベンゾキシ基
Bzl:ベンジル基
NO2:ニトロ基
2.4―DNP:2,4―ジニトロフエニルヒド
ラゾン誘導体
Py・SO3:三酸化イオウ・ピリジン錯体
al:アミノ酸残基の略号と供に用いα
―アミノアルデヒドを表わす。
ol:アミノ酸残基の略号と供に用いβ
―アミノアルコールを表わす。
OMe:メチルエステル
参考例1 Boc―L―Lys(Z)―olの合成
Boc―L―Lys(Z)―OH380mg(1ミリモル)
の20%メタノールベンゼン溶液に2M―トリメチ
ルシリルジアゾメタン―ヘキサン溶液0.7mlを5
分間で加え、室温で20分間撹拌する。反応溶液を
減圧下留去し、反応容器をアルゴンガスで置換
し、塩化リチウム85mg(2m mol)、水素化ホウ
素ナトリウム76mg(2ミリモル)とテトラハイド
ロフラン―エタノール(1:2容量比)9mlを加
え、室温化一夜撹拌する。反応溶液を減圧下留去
し、10%クエン酸水溶液10mlを加え塩化メチレン
30mlで3回抽出し、塩化メチレン層を無水芒硝で
乾燥する。溶媒留去後、無色の結晶としてBoc―
L―Lys(Z)―olが得られる。収量358mg(98
%)これをエーテル―n―ヘキサンより再結晶し
無色針状晶を得た。
融点;69〜71℃、〔α〕20 D―9.25(C=1、メタノ
ール)
参考例 2〜12
参考例1と全く同一条件でBoc―L―Lys(Z)
―OHをBoc―L―Ala―OH(参考例2)、Boc―
L―Val―OH(3)、Boc―L―Leu―OH(4)、Boc
―L―Pro―OH(5)、Z―L―Pro―OH(6)、Boc
―L―Met―OH(7)、Z―L―Phe―OH(8)、Z―
L―Cys(Bzl)OH(9)、Boc―L―Typ―OH(10)、
Boc―L―Tyr(Bzl)―OH(11)、Boc―L―Arg
(NO2)―OH(12)に変え各種アミノアルコールを
合成した。
The present invention relates to a method for producing optically active α-amino aldehydes and peptide aldehydes by oxidizing optically active β-amino alcohols as raw materials. Optically active α-aminoaldehydes are compounds useful as synthetic intermediates for bestatin, pepstatin, amastatin, and the like. On the other hand, among optically active peptide aldehydes, leupeptin, antipain, chymostatin, and elastatinal have been discovered as enzyme inhibitors produced by microorganisms, but these have argininal and phenylalaninal as C-terminal residues, respectively. , contains alaninal. These optically active peptide aldehydes are compatible with various proteases such as plasmin, trypsin, papain,
Strongly inhibits chymotrypsin, esterase, etc. In addition, these enzyme inhibitors have been in the spotlight in recent years as they have been reported to have anti-inflammatory effects, anti-ulcer effects, inhibition of mutation induction, prevention of ascites accumulation, prevention of carcinogenesis and cancer metastasis, and other effects on many diseases. The conventional method for synthesizing α-aminoaldehydes is α-
Reduction method of amino acid derivatives and β derived from α-amino acids
- Can be broadly classified into those made by oxidation of amino alcohols. As a reduction method, sodium amalgam reduction of N-protecting group α-amino acid ester (J.Biol.
Chem., Vol. 217, p. 317, 1955), diisobutylaluminum hydride reduction (Chem.Pharm.Bull.,
23, p. 3081, 1975), N-phthaloyl-α-
Rosenmund reduction of amino acid chlorides (J.Org.
Chem., vol. 18, p. 297, 1953), lithium aluminum hydride reduction of N-protected α-amino acid pyrazolide or 3,5-dimethylpyrazolide (Ann., vol. 640, p. 11, 1961, J. Antibiotics,
Volume 29, page 600, 1976, J.Med.Chem., volume 20, 510
(1977), diisobutylaluminum hydride reduction of N-protected α-amino acid imidazolides (JC
S.Chem.Comm., p. 79, 1979) and catalytic reduction of N-protected α-amino acid mixed acid anhydrides (Chem.
Pharm.Bull., vol. 30, p. 361, 1972), but all of these are obtained as a mixture of raw materials and by-products, and α-aminoaldehydes are unstable to purification methods such as silica gel. As a result of racemization, it has not been possible to obtain α-aminoaldehydes as a single optically pure product. For this reason, the known reduction method requires a two-step operation of protecting and purifying the aldehyde moiety of α-aminoaldehyde and deprotecting it, and also has the drawback of low yield. Also, as an oxidation method, Fitzner-Moffat oxidation of β-amino alcohols (Chem.Pharm.
Bull., vol. 20, p. 361, 1972), chromic acid-pyridine oxidation (J.Org.Chem., vol. 46, p. 4797, 1981)
(2013) are known, but all of these methods only yield mostly racemized α-amino aldehydes. In addition, 3- derived from α-amino acid
Although there are examples of obtaining optically active compounds by glycol oxidative cleavage of amino-1,2-diols using periodic acid, the number of steps from α-amino acids is long and the practicality is poor, and its generality has not been confirmed. No (JCSChem.Comm., p. 875, 1979). As described above, the known methods are unsatisfactory due to drawbacks such as low yields, the need to protect aldehyde groups for purification, and long steps. For this reason, until now, the physical properties of optically pure α-aminoaldehydes are largely unknown. As a result of various studies, the present inventors discovered that sulfur trioxide complex and dimethyl sulfoxide were allowed to act on optically active β-amino alcohols or peptide alcohols in the presence of triethylamine to oxidize the optically active β-amino alcohols or peptide alcohols in a short period of time. The present invention was completed by discovering a new production method for obtaining active α-amino aldehydes or peptide aldehydes as optically pure products. Furthermore, J.
ACS, Vol. 86, p. 5505, 1967, there are reports that alcohols are oxidized to aldehydes, but as in the present invention, optically active β-amino alcohols are converted to optically active α-amino alcohols. No report has yet been found on the production of aldehydes, and by carrying out the method of the present invention, it has become possible to produce excellent optically active α-aminoaldehydes or peptide aldehydes as described below. The method of the present invention can be expressed as a chemical formula as shown below. (In the formula, R 1 is an amino protecting group, an amino acid residue, a peptide residue, an amino acid residue or a peptide residue with all or part of the functional group protected, R 2 and R 4 are a hydrogen atom or an alkyl group, R 3 is a hydrogen atom, an alkyl group, or an aryl group, and the alkyl group and aryl group may be unsubstituted or substituted.) The amino protecting group for R 1 is commonly used in peptide synthesis, etc. A tert-butoxycarbonyl group, a carbobenzoxy group, a benzyl group, a tosyl group, etc. can be used. Regarding R 3 , specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 1-methylpropyl,
Carboxymethyl, 0-benzyloxymethyl,
β-carboxyethyl, β-methylthioethyl,
Benzyl, S-benzylthiomethyl, 4-benzyloxybenzyl, 3,4-dimethoxybenzyl, imidazolylmethyl, 3,4-methylenedioxybenzyl, phenyl, 4-benzyloxyphenyl, N-nitroguanidinopropyl, N 〓―
Boc-aminobutyl, N〓-Boc-aminopropyl, indolylmethyl group, etc. Next, the method of the present invention will be explained. The method for synthesizing β-amino alcohol or peptide alcohol shown by the above formula (1) is as follows:
Although various synthesis methods can be applied, one example is as follows. First, an N-protected amino acid is dissolved in a methanol-benzene mixed solvent, and trimethylsilyldiazomethane is reacted at room temperature. The reaction solvent is distilled off under reduced pressure. After replacing the reaction vessel with argon gas, etc., the tetrahydrofuran/ethanol solvent is added. dissolved in
β-amino alcohol can be easily obtained by adding lithium chloride and sodium borohydride and reacting at room temperature. The product is isolated by distilling off the solvent from the reaction solution, followed by extraction with a solvent such as methylene chloride, washing, drying, and then distilling off the solvent to easily obtain the product as crystals or oil. Obtainable. On the other hand, for peptide alcohol, the methyl ester of the peptide is obtained by a conventional method, and this is added to tetrahydrofuran,
It can be obtained by adding lithium chloride, sodium borohydride and ethanol and reacting under argon gas. The obtained product can be used as it is in the next reaction, but it can be purified by recrystallization in a suitable solvent such as n-hexane, ethyl acetate, methylene chloride, ether/n-hexane, ethyl acetate/n-hexane, etc. Alternatively, it is preferable to purify the product by vacuum distillation or column chromatography and use it in the next reaction. Next, this β-amino alcohol or peptide alcohol and triethylamine are mixed in anhydrous dimethyl sulfoxide and oxidized by adding a solution of a sulfur trioxide complex in anhydrous dimethyl sulfoxide to produce optically active α-amino aldehyde or peptide aldehyde. It is sufficient that the amounts of triethylamine and sulfur trioxide complex used are 2.5 equivalents each, but it is appropriate to use about 3 equivalents. As the sulfur trioxide complex, a complex of sulfur trioxide and pyridine, dioxane, trimethylamine, DMF, or the like can be used.
A reaction time of several minutes to more than ten minutes is sufficient, and the reaction temperature may be room temperature. Anhydrous dimethyl sulfoxide acts as a solvent, but
Benzene, methylene chloride, etc. can also be used if necessary. After the reaction is complete, the reaction mixture is poured into ice water and the product is dissolved in an appropriate solvent such as ether or ethyl acetate-benzene (4:1), washed with an aqueous citric acid solution, water, saturated aqueous sodium bicarbonate, etc., and then dried. When the solvent is distilled off, optically active α-amino aldehydes and peptide aldehydes are obtained as products. The obtained optically active α-amino aldehydes and peptide aldehydes can be used as enzyme inhibitors, etc. without any purification, but crystalline ones can be recrystallized from a suitable solvent. As described above, the method of the present invention provides a new method for producing α-amino aldehyde with high yield and high optical purity using simple operations from β-amino alcohol that can be easily obtained from α-amino acids. The present invention will be explained using examples and examples, but the scope of the present invention is not limited thereby. The abbreviations in this text have the following meanings. Ala: Alanine residue Val: Valine residue Leu: Leucine residue Pro: Proline residue Met: Methionine residue Trp: Tryptophan residue Tyr: Tyrosine residue Lys: Lysine residue Glu: Glutamic acid residue Cys: Cysteine residue Arg: Arginine residue Phe: Phenylalanine residue Gly: Glycine residue Boc: Tertiary butoxycarbonyl group Z: Carbobenzoxy group Bzl: Benzyl group NO 2 : Nitro group 2.4-DNP: 2,4-dinitrophenyl Hydrazone derivative Py SO 3 : Sulfur trioxide pyridine complex al: Used with the abbreviation of amino acid residue α
-Represents aminoaldehyde. ol: Used with the abbreviation of amino acid residue β
-Represents amino alcohol. OMe: Methyl ester reference example 1 Synthesis of Boc-L-Lys(Z)-ol Boc-L-Lys(Z)-OH 380 mg (1 mmol)
Add 0.7ml of 2M-trimethylsilyldiazomethane-hexane solution to 20% methanol benzene solution.
Add for 20 minutes and stir at room temperature for 20 minutes. The reaction solution was distilled off under reduced pressure, the reaction vessel was replaced with argon gas, and 85 mg (2 mmol) of lithium chloride, 76 mg (2 mmol) of sodium borohydride, and 9 ml of tetrahydrofuran-ethanol (1:2 volume ratio) were added. Add and stir overnight at room temperature. The reaction solution was distilled off under reduced pressure, 10 ml of 10% citric acid aqueous solution was added, and methylene chloride was added.
Extract with 30 ml three times, and dry the methylene chloride layer with anhydrous sodium sulfate. After evaporation of the solvent, Boc-
L-Lys(Z)-ol is obtained. Yield 358 mg (98
%) This was recrystallized from ether-n-hexane to obtain colorless needle crystals. Melting point: 69-71℃, [α] 20 D -9.25 (C = 1, methanol) Reference Examples 2-12 Boc-L-Lys (Z) under exactly the same conditions as Reference Example 1
-OH to Boc-L-Ala-OH (Reference Example 2), Boc-
L-Val-OH(3), Boc-L-Leu-OH(4), Boc
-L-Pro-OH(5), Z-L-Pro-OH(6), Boc
-L-Met-OH(7), Z-L-Phe-OH(8), Z-
L-Cys(Bzl)OH(9), Boc-L-Typ-OH(10),
Boc-L-Tyr(Bzl)-OH(11), Boc-L-Arg
Various amino alcohols were synthesized by replacing (NO 2 )-OH(12).
【表】
実施例1 Z―L―Phe―alの合成
Z―L―Phe―ol570mg(2ミリモル)、トリエ
チルアミン607mg(3ミリモル)、無水ジメチルス
ルホキシド6ml溶液に室温撹拌下、Py・SO3955
mg(6ミリモル)、無水ジメチルスルホキシド6
ml溶液を加え10分間撹拌し、氷水60ml中に反応溶
液をあけ水層をエーテル40mlで3回抽出し、エー
テル層は10%クエン酸、水、飽和重曹水の順に30
mlで2回各々を洗浄し無水芒硝で乾燥する。溶媒
留出後無色の結晶としてZL―Phe―alが生成物と
して得られる。収量567mg(100%)、このものを
エーテル―n―ヘキサンより再結晶した無色針状
晶を得た。収量480mg(85%)、融点;77〜9℃、
〔α〕20 D+44.5(C=1、塩化メチレン)
実施例 2〜13
実施例1と全く同一条件でZ―L―Phe―olを
Boc―L―Ala―ol(実施例2)、Boc―L―Val―
ol(3)、Boc―L―Leu―ol(4)、Boc―L―Pro―ol
(5)、Z―L―Pro―ol(6)、Boc―L―Met―ol(7)、
Boc―L―Trp―ol(8)、Boc―L―Tyr(Bzl)―
ol(9)、Boc―L―Lys(Z)―ol(10)、Z―L―Cys
(Bzl)―ol(11)、Boc―L―Arg(NO2)―ol(12)、
Boc―L―Glu(Bzl)―ol(13)に変え各種α―ア
ミノアルデヒドを合成した。[Table] Example 1 Synthesis of Z-L-Phe-al Z-L-Phe-ol 570 mg (2 mmol), triethylamine 607 mg (3 mmol), anhydrous dimethyl sulfoxide 6 ml solution under room temperature stirring, Py SO 3 955
mg (6 mmol), anhydrous dimethyl sulfoxide 6
ml solution and stirred for 10 minutes, poured the reaction solution into 60 ml of ice water and extracted the aqueous layer three times with 40 ml of ether.
ml twice and dried with anhydrous sodium sulfate. After distilling off the solvent, ZL-Phe-al is obtained as colorless crystals. The yield was 567 mg (100%), and this product was recrystallized from ether-n-hexane to obtain colorless needle crystals. Yield 480mg (85%), melting point: 77-9℃,
[α] 20 D +44.5 (C = 1, methylene chloride) Examples 2 to 13 Z-L-Phe-ol was prepared under exactly the same conditions as Example 1.
Boc-L-Ala-ol (Example 2), Boc-L-Val-
ol(3), Boc-L-Leu-ol(4), Boc-L-Pro-ol
(5), Z-L-Pro-ol (6), Boc-L-Met-ol (7),
Boc-L-Trp-ol(8), Boc-L-Tyr(Bzl)-
ol(9), Boc-L-Lys(Z)-ol(10), Z-L-Cys
(Bzl)-ol(11), Boc-L-Arg( NO2 )-ol(12),
Various α-amino aldehydes were synthesized in place of Boc-L-Glu(Bzl)-ol (13).
Claims (1)
プチド残基、官能基の全部又は一部を保護したア
ミノ酸残基またはペプチド残基、R2及びR4は水
素原子又はアルキル基、R3は水素原子、アルキ
ル基もしくはアリール基であり、アルキル基及び
アリール基は無置換であつてもよく置換されてい
てもよい) で示される光学活性β―アミノアルコール類にジ
メチルスルホキシド中トリエチルアミン存在下三
酸化イオウ錯体を反応させることを特徴とする一
般式【式】(R1,R2,R3,R4は前 記と同様) で示される光学活性α―アミノアルデヒド類の製
造法。[Claims] 1. General formula (In the formula, R 1 is an amino protecting group, an amino acid residue, a peptide residue, an amino acid residue or a peptide residue with all or part of the functional group protected, R 2 and R 4 are a hydrogen atom or an alkyl group, R 3 is a hydrogen atom, an alkyl group, or an aryl group, and the alkyl group and the aryl group may be unsubstituted or substituted). A method for producing optically active α-aminoaldehydes represented by the general formula [Formula] (R 1 , R 2 , R 3 , and R 4 are the same as above), which comprises reacting a sulfur oxide complex.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57031818A JPS58150556A (en) | 1982-03-02 | 1982-03-02 | Method for producing optically active α-aminoaldehydes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57031818A JPS58150556A (en) | 1982-03-02 | 1982-03-02 | Method for producing optically active α-aminoaldehydes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58150556A JPS58150556A (en) | 1983-09-07 |
| JPH0229670B2 true JPH0229670B2 (en) | 1990-07-02 |
Family
ID=12341664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57031818A Granted JPS58150556A (en) | 1982-03-02 | 1982-03-02 | Method for producing optically active α-aminoaldehydes |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58150556A (en) |
-
1982
- 1982-03-02 JP JP57031818A patent/JPS58150556A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58150556A (en) | 1983-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ibuka et al. | A highly stereoselective synthesis of (E)-alkene dipeptide isosteres via organocyanocopper-Lewis acid mediation reaction | |
| CA1329862C (en) | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | |
| US5510333A (en) | Inhibitors of Cathepsin G and elastase for preventing connective tissue degradation | |
| WO2005105826A1 (en) | Tyropeptin a analogue | |
| CN1067249A (en) | Amidinophenylalanine derivatives and their preparation and use | |
| EP0215335A2 (en) | Process for preparing N-/1(S)-ethoxycarbonyl-3-phenylpropyl/-L-alanyl-L-proline | |
| RU2152953C1 (en) | Derivatives of dipeptide p-amidinobenzylamides with n-terminal sulfonyl residues and their salts with physiologically acceptable acids | |
| JPS61194097A (en) | Novel peptide and peptide derivative, manufacture and medicinal composition | |
| HU201961B (en) | Process for producing 2,3-disubstituted isoxazolidines and pharmaceutical compositions comprising same | |
| CA1104156A (en) | Analogues of bestatin | |
| EP0309324A1 (en) | Process for the preparation of N-alkylated amino acids and their esters, use in the synthesis of carboxyalkyl dipeptides | |
| CH635571A5 (en) | TETRAPEPTIDES AND THERAPEUTIC COMPOSITION CONTAINING THEM. | |
| EP1268398B1 (en) | Novel method for synthesis of n- (s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril | |
| JPH0229670B2 (en) | ||
| CN105392891B (en) | Process for producing D-or L-amino acid derivative having thiol group | |
| EP0210896A1 (en) | Optically pure derivates of 4-amino-3-hydroxycarboxylic acids and process for stereospecific synthesis | |
| CA2361475A1 (en) | Process for the preparation of .alpha.-aminoketones | |
| JPH09512012A (en) | Synthesis of N-Boc-L-propargylglycine by zinc-mediated addition of organic halides to glycine cation equivalents | |
| EP1123919A1 (en) | Process for producing peptidyl aldehydes | |
| US4283328A (en) | Preparation of dehydropeptides | |
| JPH0548237B2 (en) | ||
| CA2536926C (en) | Novel method for synthesizing esters of n-[(s)-1-carboxybutyl]-(s)-alanine and use thereof for synthesizing perindopril | |
| Ohnishi et al. | The Synthesis and Reaction of Monohalogeno-t-butyloxycarbonylamino Acids | |
| US4350628A (en) | Preparation of dehydropeptides | |
| Hlaváček et al. | An Alternative Synthesis of Ψ (CH 2 O) Pseudodipeptides |